Aurinia Pharmaceuticals Inc.
10.00%
13,044,106
1600620
Jun 1, 2026
Jun 4, 2026, 06:44 PM
Reporting Persons (6)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT, LLC | Other | 10.00% | 13,044,106 | 0 | 13,044,106 |
| KEVIN TANG | Individual | 10.00% | 13,044,106 | 0 | 13,044,106 |
| TANG CAPITAL PARTNERS, LP | Partnership | 5.60% | 7,205,442 | 0 | 7,205,442 |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | Partnership | 4.00% | 5,239,039 | 0 | 5,239,039 |
| TANG CAPITAL PARTNERS III, INC | CO | 0.20% | 324,814 | 0 | 324,814 |
| TANG CAPITAL PARTNERS IV, INC | CO | 0.20% | 274,811 | 0 | 274,811 |
Disclosure Items (6)
Common Shares, no par value
Aurinia Pharmaceuticals Inc.
#140, 14315 - 118 Avenue, Edmonton, A0, T5L 4S6
The information previously provided in response to Item 2 is hereby amended and restated by replacing the text thereof in its entirety with the following: This Statement is voluntarily filed by TCM, a Delaware limited liability company that is the general partner of TCP; Kevin Tang, a United States citizen who is the manager of TCM and a member of the Board of Directors and Chief Executive Officer of the Issuer; TCP, a Delaware limited partnership engaged in capital management; TCP III, a Nevada corporation that is indirectly wholly owned by TCP and TCP IV, a Nevada corporation that is indirectly wholly owned by TCP (collectively with TCM, Kevin Tang, TCP and TCP III the "Reporting Persons").
The address of TCM, Kevin Tang, TCP and TCPI is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101.
Kevin Tang is the manager of TCM. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV.
During the past five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
See Item 2(a) above
The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 13,044,106 of the Issuer's Common Shares, representing 10.0% of the outstanding shares.
See item 5(a) above.
Schedule A attached hereto as Exhibit 2 describes all transactions in the Issuer's Common Shares that were effected during the past 60 days by the Reporting Persons.
No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Shares beneficially owned by the Reporting Persons.
Not applicable
The information previously provided in response to Item 6 is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons have potential obligations to purchase 1,000,000 of the Issuer's Common Shares pursuant to put option contracts that expire on January 15, 2027 with a strike price of $15.00.
Exhibit 1: Joint Filing Agreement by and among the Reporting Persons (filed as Exhibit 1 of the 13D filed on March 4, 2025 by the Reporting Persons with respect to the Common Shares of the Issuer). Exhibit 2: Schedule A: Transactions during the past 60 days (as amended).